Spironolactone for heart failure - Diegori.it

Spironolactone for heart failure13/06/2011 17:04in the placebo group). Were the differences in mortality and hospitalization maintained aftercontrolling for NYHA class?. Thanks for your answer.J. Ena MD (Alicante. Spain)As you note, about one quarter of patients dropped out during the course of the study.The authors do not detail the reasons for dropping out, other than to say it was "becauseof a lack of response, because of adverse events, or for administrative reasons". Thesepatients were included in the analysis of the results.Although there were slightly more patients in severe CHF in the placebo group, thereduction in mortality was almost identical when subgroups according to NYHA classwere looked at. -- mjJanuary 24, 2000Letters to the Editor about this article, from the January 13 New England Journal of Medicine.Topics covered include:Was conventional therapy maximized?Danger of hyperkalemia in diabeticsDanger of hyperkalemia in the geriatric populationRole of the beta-adrenergic systemSubmit a commentJournal Club homepagehttp://www.journalclub.org/vol2/a72.htmlPage 8 of 8